collection
MENU ▼
Read by QxMD icon Read
search

Psoriasis

shared collection
6 papers 100 to 500 followers
https://www.readbyqxmd.com/read/23769296/efficacy-and-safety-of-ustekinumab-in-patients-with-active-psoriatic-arthritis-1-year-results-of-the-phase-3-multicentre-double-blind-placebo-controlled-psummit-1-trial
#1
RANDOMIZED CONTROLLED TRIAL
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluís Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn, Mittie K Doyle
BACKGROUND: Many patients with psoriasis develop psoriatic arthritis, a chronic inflammatory disease that afflicts peripheral synovial, axial, and entheseal structures. The fully human monoclonal antibody ustekinumab is an efficacious treatment for moderate-to-severe plaque psoriasis. We did a randomised, placebo-controlled, phase 3 trial to assess the safety and efficacy of ustekinumab in patients with active psoriatic arthritis. METHODS: In this phase 3, multicentre, double-blind, placebo-controlled trial at 104 sites in Europe, North America, and Asia-Pacific, adults with active psoriatic arthritis (≥5 tender and ≥5 swollen joints, C-reactive protein ≥3·0 mg/L) were randomly assigned (1:1:1, by dynamic central randomisation based on an algorithm implemented by an interactive voice-web response system) to 45 mg ustekinumab, 90 mg ustekinumab, or placebo at week 0, week 4, and every 12 weeks thereafter...
August 31, 2013: Lancet
https://www.readbyqxmd.com/read/24940651/killing-two-birds-with-one-stone-oral-tofacitinib-reverses-alopecia-universalis-in-a-patient-with-plaque-psoriasis
#2
LETTER
Brittany G Craiglow, Brett A King
No abstract text is available yet for this article.
December 2014: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/25313095/safety-and-efficacy-of-brodalumab-for-psoriasis-after-120-weeks-of-treatment
#3
Kim Papp, Craig Leonardi, Alan Menter, Elizabeth H Z Thompson, Cassandra E Milmont, Greg Kricorian, Ajay Nirula, Paul Klekotka
BACKGROUND: Brodalumab (anti-interleukin-17-receptor antibody) was effective in treating moderate to severe psoriasis in a 12-week, dose-ranging, placebo-controlled trial. OBJECTIVE: We sought to evaluate efficacy and safety of long-term brodalumab treatment. METHODS: In this interim analysis at week 120 of an open-label extension study, patients received brodalumab 210 mg every 2 weeks. Protocol amendments reduced the dose (140 mg) in patients weighing 100 kg or less and subsequently increased the dose (210 mg) in patients with inadequate responses...
December 2014: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/24441097/transcriptome-analysis-of-psoriasis-in-a-large-case-control-sample-rna-seq-provides-insights-into-disease-mechanisms
#4
Bingshan Li, Lam C Tsoi, William R Swindell, Johann E Gudjonsson, Trilokraj Tejasvi, Andrew Johnston, Jun Ding, Philip E Stuart, Xianying Xing, James J Kochkodan, John J Voorhees, Hyun M Kang, Rajan P Nair, Goncalo R Abecasis, James T Elder
To increase our understanding of psoriasis, we used high-throughput complementary DNA sequencing (RNA-seq) to assay the transcriptomes of lesional psoriatic and normal skin. We sequenced polyadenylated RNA-derived complementary DNAs from 92 psoriatic and 82 normal punch biopsies, generating an average of ∼38 million single-end 80-bp reads per sample. Comparison of 42 samples examined by both RNA-seq and microarray revealed marked differences in sensitivity, with transcripts identified only by RNA-seq having much lower expression than those also identified by microarray...
July 2014: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/23677316/do-tnf-inhibitors-reduce-the-risk-of-myocardial-infarction-in-psoriasis-patients
#5
April W Armstrong
OBJECTIVE: To assess whether patients with psoriasis treated with tumor necrosis factor (TNF) inhibitors have a decreased risk of myocardial infarction (MI) compared with those not treated with TNF inhibitors. DESIGN: Retrospective cohort study. SETTING: Kaiser Permanente Southern California health plan. PATIENTS: Patients with at least 3 International Classification of Diseases, Ninth Revision, Clinical Modification, codes for psoriasis (696...
May 15, 2013: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/24942203/comorbidities-and-health-related-quality-of-life-in-spanish-patients-with-moderate-to-severe-psoriasis-a-cross-sectional-study-arizona-study
#6
MULTICENTER STUDY
Jose Luis Sanchez-Carazo, Jose Luis López-Estebaranz, Cristina Guisado
Psoriasis is a common, chronic inflammatory immunologically mediated disease of the skin, showing a high prevalence of associated comorbidities, and strongly affecting patients' health-related quality of life (HR-QOL), with profound impact on the psychological aspect. We aimed to establish the correlation between HR-QOL and the associated comorbidities in patients with moderate to severe psoriasis in Spain. A cross-sectional, observational, epidemiological study was conducted at 68 dermatology-based centers across Spain...
August 2014: Journal of Dermatology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"